APOE and Alzheimer disease: Our findings in the degus, together with the interesting data presented by Antes et al. (2013) on apolipoprotein E4 (apoE4) targeted replacement mice (a transgenic model with apoE4 being the most prevalent genetic risk factor for AD) arrive to similar conclusions that changes at presynaptic terminals and glutamatergic nerve terminals may be preferentially affected (Antes et al., 2013).